Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Filed when an exchange notifies the company of non-compliance with a continued-listing standard (minimum bid price, market cap, stockholders' equity) or initiates delisting. Includes the rule and the company's planned response.
Recent disclosures
-
Reviva Pharmaceuticals to be delisted from Nasdaq May 14, 2026; will trade on OTCQB
-
Intrusion Inc. receives Nasdaq deficiency notice for bid price below $1.00
-
BIO-key receives Nasdaq delisting notice; stock to move to OTC Markets on May 13
-
SkinHealth receives Nasdaq deficiency notice for bid price below $1.00
-
Maison Solutions receives Nasdaq notice for missing annual meeting deadline
-
Lunai Bioworks gets additional Nasdaq delisting notice for MVLS; completes $20M merger
-
AGAE receives Nasdaq delisting notice over bid price <$1.00 and late 10-K; will appeal
-
Picard Medical raises $5M in public offering, receives NYSE American delisting notice for low equity
-
Purple Innovation receives Nasdaq delisting determination; will appeal by May 12
-
Kezar Life Sciences acquired by Aurinia for $6.955/sh + CVR; stock to be delisted
-
Udemy acquired by Coursera; shareholders receive 0.800 Coursera shares per share
source · SEC Form 8-K instructions · see methodology